YD Bio Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $596.8K+16.9% YoYTTM through 31 Dec 2025
Net Income -$8.3MTTM through 31 Dec 2025
Free Cash Flow -$8MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 28.1% |
| EBITDA Margin | -880.6% |
| Operating Margin | -882.7% |
| Net Margin | -1,392.6% |
Returns
291.0%ROE
-80.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio5.88x
Net Debt-$6Mnet cash position
Cash & Equivalents$6M
Quality Metrics
Altman Z-Score5.64
Piotroski F-Score1 / 9
FCF Margin-1,346.6%
Multi-Year Trend
RevenueFY2025: $596.8K
Diluted EPS-$0.12TTMFY2025: $-0.12
Dividend
No dividend
Capital Allocation
Capex Intensity241.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Sales of medical and other related products | $561.8K | View detailsRemains the primary driver of commercial revenue volume. | |
| Research and development of sales of contact lenses | $36.7K | View detailsRepresents post-market auxiliary consumer healthcare distribution. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.